Basel, Switzerland, November 16, 2017-The Istanbul Mehmet Akif Ersoy Hospital provides care for all medical indications, with specialization in cardiology and pulmonology. The hospital’s catchment area has a population of 4.5 M. It is the only training and research hospital for cardiovascular surgery on the European side of Turkey. It is also the only public hospital in Turkey with an international health accreditation awarded by the Joint Commission International. IMAEH will have more than 600 beds in 2018, including an intensive care unit with 174 beds. With PRS IMAEH will be able to identify and recruit patients also in an emergency setting. IMAEH adds more than 2 million medical records and 260,000 patient lives to PRS. Joining the PRS platform means that IMAEH will become more visible to international sponsors seeking sites for clinical trials. Patients at IMAEH will now have access to a wider range of treatment options and physicians at IMAEH will be able to offer a better standard of care. PRS performs medical data analytics on EHR-based patient data from its network of partner hospitals for the purposes of patient search and identification for clinical trials, data generation for real-world evidence, and market access activities. Clinerion guarantees patient privacy through the exclusive use of anonymized patient data, while still enabling the re-identification of candidates for clinical trials by authorized hospital staff via the use of its patent-protected “Anonymous Identification” (ANID) technology. “We are very happy to join Clinerion and PRS,” says Dr. Mehmet Ertürk, Chief Physician of IMAEH. “Patients who are candidates for clinical trials can be analyzed accurately and effectively with PRS, whilst ensuring the very important protection of personal data, patient safety, reliability of operation, and supervision. PRS allows a huge efficiency improvement in running clinical studies, by finding and identifying the target numbers of patients for enrollment in trials in a very short time and reliably. This will contribute to the increase in the number of clinical trials in our country.” “IMAEH is a great addition to the PRS platform,” says BarıŠErdoÄan, Clinerion’s Head of EEMEA. “IMAEH is the only public hospital with a Phase-I Center in Turkey. Together, we will have the chance to facilitate phase II-IV trials by enhancing standard operating procedures and leveraging state-of-the-art technology to increase speed, efficiency, and productivity.” About Clinerion Clinerion enables early patient access to innovative treatments through solutions for clinical trial patient recruitment, real-world evidence, and market access. Clinerion's PRS accelerates clinical research by radically improving the efficiency and effectiveness of trial recruitment. Clinerion’s key patient data services include data-assisted protocol optimization, site feasibility evaluation, and patient identification. Clinerion’s solutions allow member hospitals to participate in leading-edge, industry-sponsored trials and save time in patient recruitment. They enable pharmaceutical companies to gain time and save costs by streamlining operations and leveraging strategic intelligence. Clinerion’s proprietary Big Data analytics technologies leverage real-time data from electronic health records which remain under the full control of participating hospitals. Clinerion is a global data technology service company headquartered in Switzerland. Clinerion's solutions comply with international patient privacy and data security regulations. Clinerion website: www.clinerion.com Clinerion’s PRS: www.clinerion.com/index/OverviewOurSolutions/PatientRecruitmentSystem For more information, please contact: Le Vin Chin Head of Marketing and Communications Clinerion Ltd Margarethenstrasse 47, CH-4053 Basel, Switzerland Tel.: +41 61 865 60 54 media@clinerion.com
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.